MedTrace Logo

Mirabegron for Female OAB Patients: Comparison of Daytime and Nighttime Dosing

NCT03251300 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2023-03-29

No results posted yet for this study

Summary

The aim of this study is to elucidate whether night-time dosing of mirebegron can improve nocturia, compared with daytime dosing of mirabegron.

Conditions

  • Overactive Bladder Syndrome

Interventions

DRUG

daytime dosing of mirabegron

All OAB female patients will receive daytime dosing (08:00 AM) of mirabegron

DRUG

nighttime dosing of mirabegron

All OAB female patients will receive nighttime dosing (08:00 PM) of mirabegron

Sponsors & Collaborators

  • Far Eastern Memorial Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-01
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03251300 on ClinicalTrials.gov